Compare Crispr Therapeutics AG (CRSP) vs Google Inc (GOOG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs Google Inc — how do they compare? Crispr Therapeutics AG trades at $53.4 (market cap $4.88B), while Google Inc trades at $349.81 (market cap $4.24T). The key difference: Google Inc is far larger — about 868.9× Crispr Therapeutics AG's market cap, and Google Inc pays a 0.26% dividend while Crispr Therapeutics AG pays none. Which is the better fit depends on your goals — on Pluang, investors hold Crispr Therapeutics AG for 77 Days and Google Inc for 137 Days on average.
| CRSP | GOOG | |
|---|---|---|
Market Cap | $4.88B | $4.24T |
Volume | 2,861,747 | 13,937,902 |
Sector | Health | Media |
52-Week High | $74.92 | $399.06 |
52-Week Low | $44.34 | $237.49 |
Typical Hold Time | 77 Days | 137 Days |
Enterprise Value | $3.30B | $4.13T |
Dividend Yield | — | 0.26% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRISPR Therapeutics (CRSP) trades at $52.35, down 3.06% with bearish technical signals. The company shows negative profitability metrics including -$581.6M net income and -4,101.26% net margin for 2025, though revenue is expected to grow from $0 to $11M in 2026. Recent news highlights upcoming clinical data presentations and CASGEVY's commercial potential, with analyst consensus leaning bullish despite fundamental challenges.
The outlook remains speculative with significant cash burn but promising pipeline catalysts. Investment opportunity lies in gene-editing breakthroughs and CASGEVY adoption, while risks include sustained losses, clinical trial outcomes, and competitive pressure. Wall Street maintains a $67.83 price target, suggesting 30% upside if execution improves.
Alphabet (GOOG) trades at $347.37, up 0.81% with strong bullish technical signals. The company demonstrates exceptional fundamental strength with 2025 revenue of $402.84B and net income of $132.17B, maintaining robust profitability margins. Recent earnings beats and aggressive AI investments highlight growth momentum, though capital expenditure spikes have raised free cash flow concerns. Analyst consensus remains overwhelmingly positive with 87% buy ratings and a $435.24 price target.
Alphabet presents a compelling growth story with dominant market positioning and AI leadership, though investors face risks from regulatory scrutiny, intense competition, and significant capital expenditure requirements. The stock's current valuation appears reasonable relative to growth prospects, with technical indicators supporting near-term upside potential toward resistance levels around $350-352.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About Google Inc
Alphabet Inc. operates as a holding company. The Company, through its subsidiaries, provides web-based search, advertisements, maps, software applications, mobile operating systems, consumer content, enterprise solutions, commerce, and hardware products.
Read more on GOOG →
